Nanjing Olymus Pharmaceutical Technology

Nanjing Olymus Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the development of small molecule therapeutics for metabolic and inflammatory diseases. As a subsidiary of Nanjing Ruijie Pharmaceutical Technology, the company leverages a "me-too" and "best-in-class" strategy to target clinically validated pathways with high unmet medical needs. Its lead candidate, RJ4287 (also known as Orimos Therapeutics' lead asset), is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH/NASH). Olymus is also advancing a pipeline of inhibitors targeting SYK and SGK1 for indications such as psoriasis and hematological malignancies, aiming to provide effective combination therapies and monotherapies.